Treating Bone Marrow and Lung Failure with Tandem Lung/ Marrow Transplant

Lung Transplant in Tandem with Bone Marrow Transplant for Combined Lung and Bone Marrow Failure

Protocol Description

This research study evaluates the effectiveness of combined lung and bone marrow transplant (BMT) procedures for treatment of an end-stage lung disease, which can include, but is not limited to, emphysema, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease, along with bone marrow failure. Researchers believe that a lung transplant first will allow restoration of pulmonary function, which would enable patients to proceed to BMT to restore hematologic function.

Eligibility Criteria

Subject to certain exclusion criteria, this study is enrolling participants, ages 18 to 60, who have end-stage lung disease and meet criteria for lung transplantation, and who have evidence of bone marrow failure.
Males and Females: Ages 18-60

Requirements

Participants will receive a double lung transplant from a partial human leukocyte antigen-matched deceased organ donor with an identical blood type. Preparation for BMT may start 8 weeks after lung transplant. Participants will receive a reduced intensity BMT procedure, with the graft cells purged of T and B lymphocytes prior to transplantation via venous infusion. Patients will be followed for up to 2 years following transplant procedures.
Visits: 11 follow-up visits after the transplant procedures
Duration: At least 26 months

Status: Open to Enrollment

Source(s) of Support

University of Pittsburgh Medical Center

Primary Investigator

Paul Szabolcs, MD

Contact Information

For more information about the study or enrollment, please contact:
Shawna McIntyre, Clinical Research Supervisor
412-692-5552